Research at the Brigham 

One of the strengths of Brigham and Women’s Hospital/Harvard Medical School Program in Urology is the depth of research opportunities available to the residents. Our faculty are world renowned experts in a number of academic disciplines and academic life at the Brigham is very much focused on developing the future of urology.  Dr. Mark Preston leads this vision for scholarly activity as director of research. Under his leadership proposals and grants have increased exponentially over the past few years.  From a residency standpoint there are ample research opportunities and while there is a dedicated research rotation, most residents conduct research during their clinical time as well.

 

Active/Ongoing Trials

  • A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK‐3475) in Subjects with High‐Risk NMIBC unresponsive to BCG Therapy; PI: Preston; Funded by Merck

  • A Randomized, Double‐blind, Single‐Center Trial of Alvimopan (Entereg) versus Placebo in Patients undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery after Surgery (ERAS) Protocol; PI: Preston; Funded by Merck

  • EDRN Prostate MRI Biomarker Study and Reference Set; Site PI: Kibel; Funded by NCI via The University of Michigan

  • Focal MR‐Guided Focused Ultrasound Treatment of Localized Low‐Risk Prostae Cancer: Feasibility Study ; PI: Tempany; Funded by InSightec‐TxSonics, Ltd.

  • Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients; PI: Kibel; Funded by NCI

  • Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study; PI: Kibel; Funded by MDXHealth, Inc.

  • PSA level during midlife and undiagnosed prostate cancer at autopsy: Understanding tumor biology and racial disparities; PI: Preston; Funded by USAMRAA

  • Underactive Bladder: Epidemiologic Analyses, Screener Development and Validation; PI: O’Leary; Funded by NIDDK via The New England Research Institute

Active Grants

  • Androgen receptor‐regulated non‐canonical WNT signaling in prostate cancer; PI: Jia; Funded by The American Cancer Society

  • Evaluating the Fiscal and Readiness Impacts of Consolidating Care of Complex Patients in the Capitol Region; Site PI: Trinh; Funded by Uniformed Services University of the Health Services (USUHS) via Henry M Jackson Foundation for the Advancement of Military Medicine

  • Identifying Patient and Provider Factors Associated with Smoking Cessation; PI: Mossanen; Funded by the Bladder Cancer Advocacy Network

  • NCTN Lead Academic Participating Site at Dana‐Farber/Partners Cancer Care; Co‐PI: Kibel; Funded by NIH‐NCI via DFCI

  • Risk prediction of aggressive prostate cancer using baseline PSA during midlife and inherited genetic variants in African‐American and Caucasian men; PI: Preston; Funded by The Prostate Cancer Foundation

  • The role of PARP2 in prostate cancer; PI: Jia; Funded by US Army Medical Research Acquisition Activity

Grants Completed in FY21

  • Hospital‐level factors associated with racial/ethnic disparities in surgical oncology; PI: Trinh; Funded by the BRI

  • Utilization of an Electronic Health Record (EHR) based behavioral economics algorithm to maximize the benefits and reduce the harm of prostate cancer screening; Site PI: Kibel; Funded by The Prevent Cancer Foundation via Memorial Sloan Kettering Institute